[Outcome of allogeneic hematopoietic stem cell transplantation for myelofibrosis]

We retrospectively reviewed outcomes of four patients (median age: 54.5 years) who received allogeneic stem cell transplantation for myelofibrosis at our hospital. Transplantation consisted of unrelated bone marrow transplantation (BMT) (n=1), related peripheral blood stem cell transplantation (PBSCT) (n=1), and haploidentical PBSCT with post-transplant cyclophosphamide (PTCy-haplo) (n=2). The conditioning regimen was fludarabine combined with busulfan 12.8 mg/kg or melphalan 140 mg/m². All patients received a JAK2 inhibitor, which was gradually tapered and then discontinued before conditioning. The three PBSCT recipients achieved engraftment, and are alive in remission. The BMT recipient died of graft failure. PTCy-haplo, myeloablative conditioning, and JAK2 inhibitors may be useful for transplantation in patients with myelofibrosis.